Albert Einstein College of Medicine of Yeshiva University has received a $3 million grant from the Glenn Foundation for Medical Research to establish the Paul F. Glenn Center for the Biology of Human Aging Research. The grant will fund research to translate recent laboratory and animal discoveries into therapies to slow human aging.
Aging contributes to many of the debilitating and costly diseases - including cancer, cardiovascular disease and diabetes - that burden the United States and many other countries. This complex but universal condition causes individual cells and the body as a whole to decline in function. Finding the mechanisms that underlie the aging process may lead to treatments that slow aging, prevent or limit common diseases, and allow people to live healthier, longer lives.
"Unless we find protective mechanisms to delay aging, we will not make progress against age-related diseases," said Nir Barzilai, M.D., co-director of the new center as well as director of the Institute for Aging Research, the Ingeborg and Ira Leon Rennert Chair in Aging Research, and professor of medicine and of genetics at Einstein. "With this valuable grant from the Paul F. Glenn Foundation, we hope to make significant advances toward understanding the aging process and improving human health."
"The generosity of Paul F. Glenn and his foundation is a welcome shot in the arm for aging research in the United States, which is chronically underfunded," said Jan Vijg, Ph.D., co-director of the new center, the Lola and Saul Kramer Chair in Molecular Genetics, and professor and chair of genetics and professor of ophthalmology and visual sciences at Einstein. "This grant will help Einstein to maintain its position as one of the world's leaders in this rapidly growing field."